Euronext Paris

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Euronext Paris, IPH, Neoplasm, Engineering, Doctor of Philosophy, AACR, IPHA, DVM, ADC

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
  • "We are excited to present our findings on IPH45 at this year's AACR.
  • Our studies demonstrate that IPH45 effectively inhibits tumor growth both in vitro and in vivo, and it exhibits a favorable safety profile in preclinical studies," stated Prof. Eric Vivier, DVM, PhD, Chief Scientific Officer at Innate Pharma.
  • "These promising results underscore the potential of IPH45 and reflect our dedication to pioneering the next wave of cancer treatments through advanced antibody engineering.

Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

Retrieved on: 
Tuesday, March 5, 2024
Software, Research, Networks, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Satellite, Clinical Trials, Science, Biotechnology, Health, Head, Neoplasm, Immune system, NEC, Multimedia, AI, MD, Immunotherapy, TME, NGS, Health care, Patient, Corporation, Euronext Paris, Cancer, Partnership, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240305404031/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240305404031/en/
    BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.
  • The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture.
  • “Our collaboration with BostonGene has provided in-depth information on patient phenotypes in the Phase I trial.
  • “We are committed to supporting Transgene and NEC as they advance these clinical trials,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Dassault Systèmes Unveils Innovative, Collaborative Mining Solutions from GEOVIA Within the 3DEXPERIENCE Platform at PDAC 2024

Retrieved on: 
Tuesday, March 5, 2024
Data Management, Technology, Manufacturing, Professional Services, Other Manufacturing, Data Analytics, Software, Environment, Engineering, Hardware, Electronic Design Automation, Prospectors, Natural Resources, PLM, Dassault Group, NPV, Mining, Safety, 3D, MTCC, Product lifecycle, Metro Toronto Convention Centre, Consultant, PDAC, Organization, Knowledge, Motivation, Euronext Paris

GEOVIA solutions provide end-to-end virtual twin experiences focusing on the intersection of natural resources, infrastructure and urban planning.

Key Points: 
  • GEOVIA solutions provide end-to-end virtual twin experiences focusing on the intersection of natural resources, infrastructure and urban planning.
  • The GEOVIA solutions portfolio is transforming significantly to seamlessly integrate with Dassault Systèmes' 3DEXPERIENCE platform.
  • The two new roles complement the GEOVIA portfolio for mining in the 3DEXPERIENCE platform, which also includes Geology Modeler, Geoscience Referential Manager, Earth Engineering Coordinator and Pit Optimizer.
  • “We are excited to actively participate at PDAC 2024 and announce our latest advancements in mining solutions,” said Mauro DelleMonache, CEO, GEOVIA, Dassault Systèmes.

Verimatrix Streamkeeper Wins Gold in 2024 Merit Awards for Telecom Innovation

Retrieved on: 
Wednesday, February 28, 2024
Software, Entertainment, Internet, Data Management, Apps, Applications, Technology, Security, Online Privacy, Audio, Video, Licensing (Entertainment), Other Technology, Telecommunications, Consultant, Growth, Creativity, Telcom, Telecom, Euronext Paris, Wireless, Video game

Verimatrix , (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that its Verimatrix Streamkeeper took home top honors in this year’s Merit Awards for Telcom and Wireless.

Key Points: 
  • Verimatrix , (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that its Verimatrix Streamkeeper took home top honors in this year’s Merit Awards for Telcom and Wireless.
  • Verimatrix Streamkeeper combines digital content security with app protection to hunt down and take down piracy for many of the world’s entertainment leaders – including more than half a billion clients across devices.
  • "We are thrilled to congratulate the winners of the Merit Awards for Telecom and Wireless.
  • Their outstanding achievements underscore their dedication to innovation and excellence in an ever-evolving industry,” said Marie Zander, executive director for Merit Awards.

Clarins Teams Up with Dassault Systèmes to Achieve New Levels of Efficiency at Its Two French Production Sites

Retrieved on: 
Thursday, February 29, 2024
Software, Professional Services, Electronic Design Automation, Data Management, Technology, Environment, Other Manufacturing, Cosmetics, Retail, Other Professional Services, Other Technology, Manufacturing, PLM, Dassault Group, Multimedia, Clarins, 3D, Growth, Fast-moving consumer goods, Product lifecycle, DELMIA, Map, Knowledge, HQE, Euronext Paris

View the full release here: https://www.businesswire.com/news/home/20240228465297/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240228465297/en/
    Clarins will deploy Dassault Systèmes’ “Perfect Production” industry solution experience based on the 3DEXPERIENCE platform.
  • To support us, we looked for a global manufacturing solution to streamline and manage production, logistics and maintenance, as well as synchronize warehouse materials.
  • The Dassault Systèmes solutions, with its extensive knowledge of our sector, provide us with the capabilities to succeed in our strategy,” said Denis Martin, Business Support Transformation Officer, Clarins.
  • Clarins will leverage “Perfect Production” to ensure a profitable growth of its operations while guaranteeing the quality of its product.

Northleaf Profitably Exits US Toll Road Northwest Parkway

Retrieved on: 
Wednesday, February 28, 2024
Professional Services, Other Construction & Property, Transport, Finance, Construction & Property, Asset Management, Other Transport, Serial Attached SCSI, Euronext Paris, NWP, Denver International Airport, Sale, Infrastructure

Funds managed by Northleaf are divesting their stake alongside the firm’s investment partners in a joint sale of 100% of the equity interest in NWP.

Key Points: 
  • Funds managed by Northleaf are divesting their stake alongside the firm’s investment partners in a joint sale of 100% of the equity interest in NWP.
  • NWP is a ~9-mile toll road located in Denver, Colorado.
  • Among other purposes, the road serves as a vital connection between Northwest Denver and the Denver International Airport.
  • Northleaf infrastructure funds initially acquired their NWP ownership interest in 2017 and subsequently increased their ownership stake in 2023.

New Dassault Systèmes Virtual Twin Experience Helps Protect Vulnerable Patients and Educate Caregivers at Saint-Louis Hospital AP-HP in Paris

Retrieved on: 
Tuesday, February 27, 2024
Manufacturing, Biometrics, Other Health, Other Professional Services, Thought Leadership, Telemedicine, Virtual Medicine, Medical Devices, Hospitals, Electronic Design Automation, Professional Services, Data Management, Technology, Biotechnology, Health, Apps, Applications, Health Technology, Engineering, Training, Education, Hospital, Atmosphere, SIMULIA, PLM, Dassault Group, Multimedia, Physician, Dialysis, 3D, Product lifecycle, Immunodeficiency, Learning, Virus, Nursing, Control, Patient, Infection, Ventilation, Healthcare industry, Mask, Euronext Paris, Partnership

To create this virtual twin, Dassault Systèmes worked with building blueprints, coupled with a 3D scan of the room made on site using its HomeByMe mobile application to check for any discrepancies.

Key Points: 
  • To create this virtual twin, Dassault Systèmes worked with building blueprints, coupled with a 3D scan of the room made on site using its HomeByMe mobile application to check for any discrepancies.
  • Equipped with this information, Dassault Systèmes developed the augmented reality experience enabling the stakeholders to view the virtual simulations within the real-life setting.
  • “Dassault Systèmes had already worked on projects at other hospitals in Paris and understood our mission to offer the highest level of care.
  • “This incredibly innovative educational experience made our health professionals more aware of respiratory cross-transmission risks in the hospital.

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Retrieved on: 
Wednesday, February 21, 2024
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, IPHA, Euronext Paris, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below.

Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

Retrieved on: 
Tuesday, March 5, 2024
Antigen, Head, Neoplasm, Immune system, NEC, AI, MD, Immunotherapy, TME, NGS, Health care, Patient, Corporation, Euronext Paris, Cancer, Partnership, Pharmaceutical industry

BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.

Key Points: 
  • BostonGene is partnering with NEC and Transgene to continue performing tumor molecular profiling and microenvironment analysis and provide high-throughput sequencing services.
  • The partnership with BostonGene will enable fast turnaround of next-generation sequencing (NGS) data, and sophisticated analytics will enable comprehensive profiling of patient immune contexture.
  • "Our collaboration with BostonGene has provided in-depth information on patient phenotypes in the Phase I trial.
  • "We are committed to supporting Transgene and NEC as they advance these clinical trials," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

Sartorius Stedim Biotech releases Universal Registration Document 2023

Retrieved on: 
Friday, February 16, 2024
Sartorius AG, Annual, Euronext, Euronext Paris

Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.

Key Points: 
  • Sartorius Stedim Biotech, a leading partner of the biopharma industry, has released its Universal Registration Document 2023 including the Annual Financial Report today.
  • Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.